Reply to “Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma” by Mesbah Ardakani et al

Summary

Like Mesbah Ardakani et al. we investigated the impact of BRAF V600E allele frequency (AF) on progression free survival (PFS) and overall survival (OS) in patients treated by BRAF inhibitors used as single agents for advanced or metastatic melanoma but we used a larger retrospective cohort with 78 patients enrolled in two skin cancer centers.

Because BRAF mutation has a heterozygous pattern, we set the cutoff to separate high and low BRAF AF at 60%, in accordance to our previous work on this subject. Like Mesbah Ardakani et al., a high BRAF V600E AF did not significantly influence PFS or OS, but in our study there was a trend towards better clinical outcomes.

Further larger studies with a cutoff of 60% are needed to definitely conclude if BRAF AF is a biomarker of response to BRAF inhibitors used as single agents as well as used in combination regimens.

This article is protected by copyright. All rights reserved.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rGMhF7
via IFTTT